On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its personalized healthcare solutions and momentum in weight loss offerings.

Andrew Dudum has played a role in 12 plus companies, raised hundreds of millions of dollars in the process, and have created a venture producing machine. What is he up to now?

Investors, CEOs and commentators trashed Hims & Hers founder and CEO Andrew Dudum on social media Wednesday after he praised the "moral courage" of the anti-Israel protesters creating havoc on ...

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.

Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.